skip to Main Content

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
In patients with metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy, researchers sought to appraise the effectiveness of olaparib as maintenance therapy in patients who also have a germline BRCA1 or BRCA2 mutation via a randomized, double-blind, placebo-controlled, phase 3 trial.

Read more . . .


Back To Top